
|Videos|September 21, 2022
Dr. Ornstein on antibody-drug conjugates for immunotherapy-refractory urothelial carcinoma
Author(s)Urology Times staff
“The management of patients with advanced urothelial carcinoma whose cancer has progressed on immunotherapy presents a unique challenge,” says Moshe Ornstein, MD.
Advertisement
Moshe Ornstein, MD, MA, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the emergence of antibody-drug conjugates as a treatment option for patients with immune checkpoint inhibitor–refractory advanced urothelial carcinoma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants tentative approval to generic olaparib tablets across previously approved indications
2
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
3
Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC
4
Prof Declan Murphy on interpreting the PROTEUS trial in localized prostate cancer
5











